• 1
    Thorne C., Semenenko I., Malyuta R. Prevention of mother-to-child transmission of HIV among pregnant women using injecting drugs in Ukraine, 2000–10. Addiction 2012; 107: 11828.
  • 2
    Des Jarlais D. C., Friedman S. R., Novick D. M., Sotheran J. L., Thomas P., Yancovitz S. R. et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA 1989; 261: 100812.
  • 3
    The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20: 141927.
  • 4
    Wolfe D., Carrieri M. P., Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376: 35566.
  • 5
    Beyrer C., Malinowska-Sempruch K., Kamarulzaman A., Kazatchkine M., Sidibe M., Strathdee S. A. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010; 376: 55163.
  • 6
    Shapiro M. F., Morton S. C., McCaffrey D. F., Senterfitt J. W., Fleishman J. A., Perlman J. F. et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999; 281: 230515.
  • 7
    Strathdee S. A., Palepu A., Cornelisse P. G., Yip B., O'Shaughnessy M. V., Montaner J. S. et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 5479.
  • 8
    Tapp C., Milloy M. J., Kerr T., Zhang R., Guillemi S., Hogg R. S. et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis 2011; 11: 86.
  • 9
    Strathdee S. A., Hallett T. B., Bobrova N., Rhodes T., Booth R., Abdool R. et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376: 26884.
  • 10
    Garfein R. S., Vlahov D., Galai N., Doherty M. C., Nelson K. E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 65561.
  • 11
    Taran Y. S., Johnston L. G., Pohorila N. B., Saliuk T.O. Correlates of HIV risk among injecting drug users in sixteen Ukrainian cities. AIDS Behav 2011; 15: 6574.
  • 12
    Booth R. E., Kwiatkowski C. F., Brewster J. T., Sinitsyna L., Dvoryak S. Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS 2006; 20: 221723.
  • 13
    Turner B. J., Laine C., Cosler L., Hauck W. W. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003; 18: 24857.
  • 14
    Cruz M. F., Mantsios A., Ramos R., Case P., Brouwer K. C., Ramos M. E. et al. A qualitative exploration of gender in the context of injection drug use in two US-Mexico border cities. AIDS Behav 2007; 11: 25362.
  • 15
    Wagner K. D., Lankenau S. E., Palinkas L. A., Richardson J. L., Chou C. P., Unger J. B. The perceived consequences of safer injection: an exploration of qualitative findings and gender differences. Psychol Health Med 2010; 15: 56073.
  • 16
    Bourgois P., Prince B., Moss A. The Everyday Violence of Hepatitis C Among Young Women Who Inject Drugs in San Francisco. Hum Organ 2004; 63: 25364.
  • 17
    Krishnan S., Dunbar M. S., Minnis A. M., Medlin C. A., Gerdts C. E., Padian N. S. Poverty, gender inequities, and women's risk of human immunodeficiency virus/AIDS. Ann N Y Acad Sci 2008; 1136: 10110.
  • 18
    Razak M. H., Jittiwutikarn J., Suriyanon V., Vongchak T., Srirak N., Beyrer C. et al. HIV prevalence and risks among injection and noninjection drug users in northern Thailand: need for comprehensive HIV prevention programs. J Acquir Immune Defic Syndr 2003; 33: 25966.
  • 19
    Zamani S., Kihara M., Gouya M. M., Vazirian M., Ono-Kihara M., Razzaghi E. M. et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS 2005; 19: 70916.